Dupont Capital Management Corp grew its stake in shares of TG Therapeutics Inc (NASDAQ:TGTX) by 153.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 64,957 shares of the biopharmaceutical company’s stock after acquiring an additional 39,295 shares during the period. Dupont Capital Management Corp’s holdings in TG Therapeutics were worth $533,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Ameriprise Financial Inc. boosted its stake in shares of TG Therapeutics by 150.2% during the second quarter. Ameriprise Financial Inc. now owns 277,235 shares of the biopharmaceutical company’s stock valued at $2,786,000 after purchasing an additional 166,434 shares during the period. State Street Corp boosted its stake in shares of TG Therapeutics by 274.4% during the second quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock valued at $26,515,000 after purchasing an additional 1,933,896 shares during the period. Raymond James Financial Services Advisors Inc. raised its holdings in shares of TG Therapeutics by 65.0% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 81,104 shares of the biopharmaceutical company’s stock valued at $961,000 after acquiring an additional 31,958 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of TG Therapeutics by 176.8% in the third quarter. Schwab Charles Investment Management Inc. now owns 243,485 shares of the biopharmaceutical company’s stock valued at $2,886,000 after acquiring an additional 155,535 shares in the last quarter. Finally, Columbus Circle Investors raised its holdings in shares of TG Therapeutics by 9.8% in the third quarter. Columbus Circle Investors now owns 1,532,911 shares of the biopharmaceutical company’s stock valued at $18,165,000 after acquiring an additional 136,515 shares in the last quarter. 48.73% of the stock is owned by hedge funds and other institutional investors.

In other TG Therapeutics news, CFO Sean A. Power sold 32,006 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at $4,398,444. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 16.70% of the company’s stock.

Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a report on Monday, December 11th. Raymond James Financial restated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, December 12th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 11th. B. Riley assumed coverage on TG Therapeutics in a report on Friday, December 1st. They issued a “buy” rating and a $21.50 price objective for the company. Finally, ValuEngine upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. TG Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.50.

Shares of TG Therapeutics Inc (NASDAQ:TGTX) opened at $11.75 on Friday. The firm has a market capitalization of $830.16, a PE ratio of -6.09 and a beta of 1.67. TG Therapeutics Inc has a fifty-two week low of $4.50 and a fifty-two week high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). The firm had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. equities analysts forecast that TG Therapeutics Inc will post -1.87 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/02/10/tg-therapeutics-inc-tgtx-stake-increased-by-dupont-capital-management-corp.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics Inc (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.